we manufacture and provide Cangrelor intermediate with commercial capability

CAS 163706-61-4
Purity is ≥９８％

Cangrelor:

a short-acting, potent and selective small molecule P2Y12 purinoceptor antagonist and platelet ADP receptor

antagonist, is being developed by The M

edicines Company as an intravenous antithrombotic agent in the critical care

setting of the cardiac catheterisation laboratory. It is being investigated for the prevention of ischaemic events in patients

with coronary artery disease who require percutaneous coronary intervention (PCI). 

a short-acting, potent and selective small molecule P2Y12 purinoceptor antagonist and platelet ADP receptor

antagonist, is being developed by The M

edicines Company as an intravenous antithrombotic agent in the critical care

setting of the cardiac catheterisation laboratory. It is being investigated for the prevention of ischaemic events in patients

with coronary artery disease who require percutaneous coronary intervention (PCI). 

is a P2Y12 inhibitor under investigation as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion.